BR112019024509A2 - Glicuronídeo de pró-fármacos dos inibidores da janus quinase - Google Patents

Glicuronídeo de pró-fármacos dos inibidores da janus quinase Download PDF

Info

Publication number
BR112019024509A2
BR112019024509A2 BR112019024509-0A BR112019024509A BR112019024509A2 BR 112019024509 A2 BR112019024509 A2 BR 112019024509A2 BR 112019024509 A BR112019024509 A BR 112019024509A BR 112019024509 A2 BR112019024509 A2 BR 112019024509A2
Authority
BR
Brazil
Prior art keywords
methyl
compound
mmol
pct
pyran
Prior art date
Application number
BR112019024509-0A
Other languages
English (en)
Portuguese (pt)
Inventor
D. Long Daniel
Daniel D. Long
A.A. Wilton Donna
Donna A.A. Wilton
Loo Mandy
Mandy LOO
Hudson Ryan
Ryan Hudson
J. Brassil Patrick
Patrick J. Brassil
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of BR112019024509A2 publication Critical patent/BR112019024509A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112019024509-0A 2017-05-23 2018-05-22 Glicuronídeo de pró-fármacos dos inibidores da janus quinase BR112019024509A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509847P 2017-05-23 2017-05-23
US62/509,847 2017-05-23
PCT/US2018/033818 WO2018217700A1 (en) 2017-05-23 2018-05-22 Glucuronide prodrugs of janus kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112019024509A2 true BR112019024509A2 (pt) 2020-06-23

Family

ID=62621001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024509-0A BR112019024509A2 (pt) 2017-05-23 2018-05-22 Glicuronídeo de pró-fármacos dos inibidores da janus quinase

Country Status (14)

Country Link
US (2) US10745405B2 (https=)
EP (1) EP3609899A1 (https=)
JP (1) JP2020520955A (https=)
KR (1) KR20200010440A (https=)
CN (1) CN110662747A (https=)
AU (1) AU2018273866B2 (https=)
BR (1) BR112019024509A2 (https=)
CA (1) CA3063963A1 (https=)
IL (1) IL270693A (https=)
MX (1) MX2019014054A (https=)
NZ (1) NZ759764A (https=)
PH (1) PH12019502605A1 (https=)
RU (1) RU2019142472A (https=)
WO (1) WO2018217700A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
CN111196831B (zh) * 2020-01-20 2023-05-09 山西医科大学 一种呋喃酚葡萄糖醛酸结合物的制备方法
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
WO2023018954A1 (en) * 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
JP2025505812A (ja) * 2022-02-21 2025-02-28 オンクオリティ ファーマシューティカルズ チャイナ リミテッド 化合物及びその用途
CN119923257A (zh) * 2022-04-15 2025-05-02 密歇根大学董事会 Jak抑制剂类似物、制剂及其用途
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
EP4637724A1 (en) 2022-12-22 2025-10-29 KRKA, d.d., Novo mesto Veterinary composition comprising oclacitinib
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) * 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
US7798257B2 (en) 2004-04-30 2010-09-21 Smith International, Inc. Shaped cutter surface
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-d]피리미딘 화합물
EA021478B1 (ru) * 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EP2515913A2 (en) 2009-12-23 2012-10-31 Glycomyr Inc. Use of vitamin d glycosides and sulfates for treatment of disease
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
MX2012009074A (es) 2010-02-05 2012-08-23 Pfizer Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
US20140357557A1 (en) 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
RS60237B1 (sr) 2015-11-24 2020-06-30 Theravance Biopharma R&D Ip Llc Prolekovi jak inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti
CN106496233B (zh) * 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
RU2019142472A (ru) 2021-06-24
IL270693A (en) 2020-01-30
PH12019502605A1 (en) 2020-10-26
KR20200010440A (ko) 2020-01-30
JP2020520955A (ja) 2020-07-16
AU2018273866A1 (en) 2019-12-19
US10745405B2 (en) 2020-08-18
MX2019014054A (es) 2020-02-05
CA3063963A1 (en) 2018-11-29
RU2019142472A3 (https=) 2021-09-23
EP3609899A1 (en) 2020-02-19
NZ759764A (en) 2022-07-01
US20210032250A1 (en) 2021-02-04
WO2018217700A1 (en) 2018-11-29
US20180339990A1 (en) 2018-11-29
CN110662747A (zh) 2020-01-07
AU2018273866B2 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
BR112019024509A2 (pt) Glicuronídeo de pró-fármacos dos inibidores da janus quinase
US10472366B2 (en) Glucuronide prodrugs of tofacitinib
CN113811300B (zh) Tead转录因子的新型小分子抑制剂
CN109963844B (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
JP6778747B2 (ja) 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ
ES2489645T3 (es) Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
EP4549442A1 (en) Prmt5 inhibitors and use thereof
US10562864B2 (en) Chemical modulators of immune checkpoints and therapeutic use
CA2942975A1 (en) Substituted acrylamide and substituted ethenesulfonamide derivatives and pharmaceutical compositions thereof useful as amyloid targeting agents
TWI393708B (zh) 異羥肟酸脂化合物,其用途及其之合成方法
KR20140040104A (ko) 대사 및 염증 질병의 치료에 유용한 아제티딘 유도체
RS66733B1 (sr) Inhibitori alfa v beta6 integrina
CA3151776C (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
AU2015298476B2 (en) Benzodiazepine derivatives as CCK2/gastrin receptor antagonists
AU2020410900B2 (en) Compound used as RET kinase inhibitor and application thereof
WO2016107227A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
JP6298172B2 (ja) Gpr142アゴニスト化合物
JPWO2019235553A1 (ja) アゼチジン誘導体及びそのプロドラッグ
WO2016064682A1 (en) Selective inhibitors of constitutive androstane receptor
KR20170073699A (ko) 신규한 유형의 시티딘 유도체 이량체 및 그의 용도
EP4631931A1 (en) Hdac inhibitor and use thereof
CN118772107A (zh) Hdac抑制剂及其用途
CN121293163A (zh) 一种2-氨基苯基嘧啶衍生物及其制备方法与医药用途
WO2022203267A1 (ko) 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도
CN116332928A (zh) 嘧啶并吡啶酮类化合物及其应用

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements